Optic Neuritis Imaging
- Author: Pil (Peter) S Kang, MD; Chief Editor: James G Smirniotopoulos, MD more...
Magnetic Resonance Imaging
Thin (2-3mm), fat-suppressed, T2-weighted images, such as short tau inversion recovery (STIR) sequences, through the optic nerves may show characteristic high-signal intensity foci in the minimally expanded or nonexpanded nerve. These lesions frequently enhance following intravenous contrast administration, which is not seen in a healthy optic nerve. Some studies have shown that certain findings, such as optic nerve lesions of greater length and in certain locations (within the optic canal), may be associated with a worse visual prognosis and may benefit from certain treatments, but other studies have not supported this conclusion.
Diffusion-weighted and diffusion-tensor imaging may contribute more data that may prove to have some bearing on treatment and/or on prognosis.[7, 8, 9, 10] The thought is that the loss of anisotropy (manifested by an increase in the apparent diffusion coefficient or a decrease in fractional anisotropy) associated with demyelination and/or axonal damage may be more sensitive and/or yield more prognostic information than anatomic imaging findings (size, T2 signal intensity, and enhancement, which suggests loss of the blood-brain barrier due to the underlying pathologic process), which could manifest themselves much later than the findings associated with loss of anisotropy. However, with the current technology, diffusion-weighted and diffusion-tensor imaging of the optic nerves is too time- and labor-intensive for broad clinical application. MRI characteristics of optic neuropathy are demonstrated in the images below.
A 43-year-old woman with acute vision loss and eye pain. No prior neurologic symptoms were noted. Axial, fat-suppressed, postgadolinium, T1-weighted image through the orbit reveals an intensely enhancing segment of the distal left optic nerve.
A 43-year-old woman with acute vision loss and eye pain. No prior neurologic symptoms were noted. Coronal, fat-suppressed, postgadolinium, T1-weighted image demonstrates intense enhancement within the optic nerve. No significant nerve expansion or enhancement of the adjacent tissues is seen. Note the normal right optic nerve for comparison.
A 35-year-old woman with acute onset of left-eye pain and vision decline. Axial, fat-suppressed, postcontrast, T1-weighted image demonstrates enhancement in the intracanalicular portion of the left optic nerve.
A 35-year-old woman with acute onset of left-eye pain and vision decline. Axial, fluid-attenuated inversion recovery (FLAIR) image demonstrates bilateral periventricular white matter lesions. Several additional and similar lesions were seen in other locations (not shown). No history of prior neurologic illness was noted in the patient, but in the setting of acute optic neuritis, the multiple white matter lesions in a number and pattern atypical for the patient's age were considered to be supportive of the diagnosis of multiple sclerosis. Optic neuritis and MS
The real contribution of imaging in the setting of optic neuritis is made by imaging of the brain, not of the optic nerves themselves. This is due to the fact that the most valuable predictor for the development of subsequent MS is the presence of white matter abnormalities. Between 27% and 70% of patients (in various studies) with isolated optic neuritis show abnormal MRI brain findings, as defined by the presence of 2 or more white matter lesions on T2-weighted images.
In the Optic Neuritis Treatment Trial, the 5-year risk of developing MS was 16% in patients with normal brain MRI findings, 37% with 1-2 lesions, and 51% with 3 or more lesions. At 10 years, the only statistically significant difference was between no lesions (22% risk) and 1 or more lesions (56% risk).[11]
Bonhomme et al found that children with brain MRI abnormalities at the time of optic neuritis diagnosis had an increased risk for MS. The investigators studied the rate of conversion to MS after a diagnosis of optic neuritis in children (younger than 18y) who presented with optic neuritis between 1993 and 2004 at the Children's Hospital of Philadelphia.
In the study, Bonhomme and colleagues identified 29 children with idiopathic optic neuritis. Eleven of the 29 patients (38%) had white matter T2/FLAIR (fluid-attenuated inversion recovery) lesions in the brain (not including the optic nerves). Eighteen patients were followed for more than 24 months, and 3 of the 18 (17%) developed MS. All 3 patients who developed MS had an abnormal brain MRI scan at their initial presentation of optic neuritis. None of the patients who had normal MRI scans developed MS over an average follow-up period of 88.5 months.[1]
Swanton et al found that the presence and number of spinal cord lesions at baseline and of new T2 lesions at follow-up were significant independent predictors of higher disability. In their report, the investigators studied patients with optic neuritis to determine the influence of lesion number, location, and activity, as well as non-lesion MRI measures obtained on early scans. At 6-year follow-up, 48% of patients had converted to clinically definite MS, and 52% remained with clinically isolated syndrome.[12]
Disability was also predicted by the presence at baseline of gadolinium-enhancing lesions and the number of infratentorial lesions. Only spinal cord lesions predicted disability in patients converting to clinically definite MS.
The Optic Neuritis Treatment Trial found that there was a 50% cumulative probability of developing MS within 15 years after the onset of optic neuritis. The presence of lesions on a baseline, non–contrast-enhanced MRI of the brain was a significant factor in the occurrence of MS. The study also found that in patients with optic neuritis who had no lesions on baseline brain MRI, 25% developed MS during follow-up, while among patients with 1 or more lesions, 72% developed MS.[2]
Influence of MRI on treatment
Information from brain MRI has a potential influence on treatment. It has been shown that in 2-year follow-up of patients with optic neuritis and 2 or more brain lesions on MRI scans, patients given intravenous methylprednisolone (as compared with placebo and oral prednisone groups) had a significantly decreased risk of developing MS. Note that this benefit was not maintained at 3 years.[13, 14]
In a study using interferon beta-1a (Avonex) in patients with optic neuritis with 2 or more white matter lesions on MRI scans of the brain, a decreased risk of developing MS at 3 years was demonstrated. In those patients who did ultimately develop MS, interferon beta-1a was shown to reduce the disease burden and number of active lesions.[15, 16]
False positives/negatives
Although not specifically relevant to optic neuritis, false-positive results in orbital imaging can result from failure of complete fat saturation related to magnetic susceptibility artifact from dental amalgam and air–soft tissue interfaces, particularly at the inferior margin of the orbit. This is true especially for frequency-selective fat-saturation techniques but less so for inversion recovery sequences.
Fat-saturation failure can mimic orbital edema on multiecho-train, T2-weighted images or enhancement on fat-suppressed, T1-weighted images. Careful evaluation of the tissue surrounding the orbit should reveal the true cause of signal distortion. This artifact should not occur in optic neuritis, because the lesion of optic neuritis is confined to the nerve, but it can potentially mislead the interpreter to conclude that more diffuse orbital inflammation is the cause of vision loss.
Occasionally, the enhancement pattern in optic neuritis is a peripheral tram-track pattern. Potentially, this can be confused with the enhancement pattern of optic nerve meningioma. However, the optic neuritis pattern should be distinguished from the meningioma pattern by enhancement limited to the nerve, rather than the sheathlike pattern of meningioma; by the absence of significant mass or expansion; and by the clinical features of acute onset vision loss and pain.
Bonhomme GR, Waldman AT, Balcer LJ, Daniels AB, Tennekoon GI, Forman S, et al. Pediatric optic neuritis: brain MRI abnormalities and risk of multiple sclerosis. Neurology. Mar 10 2009;72(10):881-5. [Medline].
Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. Jun 2008;65(6):727-32. [Medline].
Beck RW, Gal RL, Bhatti MT, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. Jan 2004;137(1):77-83. [Medline].
Costello F, Hodge W, Pan YI. Exploring the association between retinal nerve fiber layer thickness and initial magnetic resonance imaging findings in patients with acute optic neuritis. Mult Scler Int. 2011;2011:289785. [Medline]. [Full Text].
Osborne BJ, Volpe NJ. Optic neuritis and risk of MS: differential diagnosis and management. Cleve Clin J Med. Mar 2009;76(3):181-90. [Medline].
Naismith RT, Tutlam NT, Xu J, Klawiter EC, Shepherd J, Trinkaus K, et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology. Mar 24 2009;72(12):1077-82. [Medline].
Chabert S, Molko N, Cointepas Y, et al. Diffusion tensor imaging of the human optic nerve using a non-CPMG fast spin echo sequence. J Magn Reson Imaging. Aug 2005;22(2):307-10. [Medline].
Trip SA, Wheeler-Kingshott C, Jones SJ, et al. Optic nerve diffusion tensor imaging in optic neuritis. Neuroimage. Oct 18 [Epub ahead of print] 2005;[Medline].
Hickman SJ, Wheeler-Kingshott CA, Jones SJ, et al. Optic nerve diffusion measurement from diffusion-weighted imaging in optic neuritis. AJNR Am J Neuroradiol. Apr 2005;26(4):951-6. [Medline].
Jeantroux J, Kremer S, Lin XZ, et al. Diffusion tensor imaging of normal-appearing white matter in neuromyelitis optica. J Neuroradiol. Dec 13 2011;[Medline].
Optic Neuritis Study Group. Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group. Arch Ophthalmol. Dec 1997;115(12):1545-52. [Medline].
Swanton JK, Fernando KT, Dalton CM, Miszkiel KA, Altmann DR, Plant GT, et al. Early MRI in optic neuritis: the risk for disability. Neurology. Feb 10 2009;72(6):542-50. [Medline].
Kaufman DI, Trobe JD, Eggenberger ER, Whitaker JN. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. Jun 13 2000;54(11):2039-44. [Medline].
Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol. Jun 2005;139(6):1101-8. [Medline].
Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. Sep 28 2000;343(13):898-904. [Medline].
CHAMPS Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol. Oct 2001;132(4):463-71. [Medline].

